Advertisement with HPR
Dr. Yutaka Niihara, CEO of Emmaus Life Sciences, discusses Sickle Cell Disease in underserved minority populations and his passion for finding a treatment. Now, for the first time in 20 years there is Endari, that was FDA approved in 2017, that reduces the severe complications of Sickle Cell Disease and one that is approved for use in children five years and older.
Joel Evans beats the odds and survived pancreatic cancer. Now he is on a mission to help others. In his brief, motivational memoir, SURVIVING CANCER AND EMBRACING LIFE: My Personal Journey, Evans shares his journey from the first phone call with the doctor, to today, where he's created a website and blog to support others facing a devastating diagnosis.
Dr. Mike Ybarra discusses a new national series called "Together" that features patients and industry scientists who are behind the development of treatments and cures for complex and devastating conditions. "Together" is a fundamental piece of the GOBOLDLY initiative, which showcases crucial innovation occurring in research and development to generate treatments and cures for a host of illnesses and chronic conditions.
Dr. Brian Mech, Ph.D discusses eSight - the creators of electronic glasses that enable the legally blind to actually see again. eSight is worn like a normal pair of glasses, but it houses a high-speed, high-definition camera that captures everything you are looking at, and then displays it on two near-to-eye displays.
Dr. Bruce Sands discusses his presentation of the new pivotal Phase 3 data at the American College of Gastroenterology (ACG) Annual Scientific Meeting showing that a single IV dose of STELARA® (ustekinumab) – the first and only biologic targeting interleukin (IL)-12 and -23 cytokines – induced clinical remission in a greater percentage of adult patients with moderate-to-severe ulcerative colitis (UC), compared to those receiving placebo.